211245-55-5

Basic information

• Product Name: (2-Methanesulfanyl-4-phenylamino-pyrimidin-5-yl)-methanol
• Synonyms: (2-Methanesulfanyl-4-phenylamino-pyrimidin-5-yl)-methanol
• CAS NO: 211245-55-5
• Molecular Weight: 247.321
• Mol File: 211245-55-5.mol

Chemical Properties

• CAS DataBase Reference: (2-Methanesulfanyl-4-phenylamino-pyrimidin-5-yl)-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Methanesulfanyl-4-phenylamino-pyrimidin-5-yl)-methanol(211245-55-5)
• EPA Substance Registry System: (2-Methanesulfanyl-4-phenylamino-pyrimidin-5-yl)-methanol(211245-55-5)

Safety Data

• Hazardous Substances Data: 211245-55-5(Hazardous Substances Data)

Upstream product

• 106475-47-2 2-methanesulfanyl-4-phenylamino-pyrimidine-5-carboxylic acid ethyl ester 
• 62-53-3 aniline 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 

Downstream Products

• 211245-59-9 2-methanesulfinyl-8-phenyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 211245-58-8 2-Methanesulfanyl-8-phenyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 211245-56-6 2-methanesulfanyl-4-phenylamino-pyrimidine-5-carboxaldehyde 

Relevant articles and documents

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases

The identification of 8-ethyl-2-phenylamino-8H-pyrido [2,3-d]pyrimidin-7-one (1) as an inhibitor of Cdk4 led to the initiation of a program to evaluate related pyrido [2,3-d]pyrimidin-7-ones for inhibition of cyclin-dependent kinases (Cdks). Analysis of m

Pyridopyrimidinone derivatives for treatment of neurodegenerative disease

This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-di

Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation

This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-dia

Heteroalkylamino-substituted bicyclic nitrogen heterocycles

The invention provides compounds represented by the formula: wherein R1, R2, R3, R4, and n are as defined in the Summary of the Invention; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Bicyclic nitrogen heterocycles

Amino-substituted dihydropyrimido[4,5-d]pyrimidinones of the formula in which R1 represents hydrogen, lower alkyl, aryl, aryl-lower alkyl, heteroaryl, heteroaryl-lower alkyl, lower cycloalkyl or lower cycloalkyl-lower alkyl, R2 represents lower alkyl, aryl, aryl-lower alkyl, heteroaryl, heteroaryl-lower alkyl, lower cycloalkyl or lower cycloalkyl-lower alkyl, and R3 represents hydrogen, lower alkyl, aryl, aryl-lower alkyl, heteroaryl, heteroaryl-lower alkyl, lower cycloalkyl, lower cycloalkenyl or lower cycloalkyl-lower alkyl, and pharmaceutically acceptable salts thereof are protein kinase inhibitors. They can be used in the treatment or prophylaxis of inflammatory, immunological, oncological, bronchopulmonary, dermatological and cardiovascular disorders, in the treatment of asthma, central nervous system disorders or diabetic complications or for the prevention of graft rejection following transplant surgery.